![](/img/cover-not-exists.png)
Long-term cost-effectiveness analysis shows that IDegLira is associated with improved outcomes and lower costs compared with insulin glargine U100 plus insulin aspart in the US
Dempsey, Michael, Mocarski, Michelle, Langer, Jakob, Hunt, BarnabyLanguage:
english
Journal:
Journal of Medical Economics
DOI:
10.1080/13696998.2018.1513406
Date:
September, 2018
File:
PDF, 1.02 MB
english, 2018